Drug Profile
Cefoselis
Alternative Names: FK 037; WincefLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Class Antibacterials; Cephalosporins; Oximes; Small molecules
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Bacterial infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in European Union (Parenteral)
- 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
- 10 Sep 1998 Launched for Bacterial infections in Japan (Parenteral)